Greenspring Associates

Location

United States

Total investments

234

Average round size

72M

Portfolio companies

166

Rounds per year

10.17

Lead investments

43

Follow on index

0.29

Exits

74

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyE-CommerceInternetSoftwareAnalyticsInformation TechnologyHealth CareSaaSEnterprise SoftwareMedical

Summary

In 2000 was created Greenspring Associates, which is appeared as VC. The company was established in North America in United States. The main office of represented VC is situated in the Owings Mills.

The fund was created by Ashton Newhall. Besides them, we counted 7 critical employees of this fund in our database.

The fund is constantly included in 7-12 investment rounds annually. Deals in the range of 50 - 100 millions dollars are the general things for fund. The average startup value when the investment from Greenspring Associates is 500 millions - 1 billion dollars. The top activity for fund was in 2019. The top amount of exits for fund were in 2015. Considering the real fund results, this VC is 7 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Greenspring Associates performs on 18 percentage points more the average number of lead investments.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Greenspring Associates, startups are often financed by Sequoia Capital, Scale Venture Partners, OpenView Venture Partners. The meaningful sponsors for the fund in investment in the same round are e.ventures, Cross Creek, OpenView Venture Partners. In the next rounds fund is usually obtained by Silicon Valley Bank, OpenView Venture Partners, Domain Associates.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Enterprise Software, Health Care. Among the most popular portfolio startups of the fund, we may highlight Alibaba, Intarcia Therapeutics, Zayo. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
234
Lead investments
43
Exits
74
Rounds per year
10.17
Follow on index
0.29
Investments by industry
  • Software (73)
  • Health Care (56)
  • SaaS (40)
  • Biotechnology (37)
  • Enterprise Software (36)
  • Show 226 more
Investments by region
  • United States (206)
  • Germany (2)
  • Israel (4)
  • Canada (3)
  • United Kingdom (4)
  • Show 5 more
Peak activity year
2021
Number of Unicorns
29
Number of Decacorns
31
Number of Minotaurs
9

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
14
Avg. valuation at time of investment
959M
Group Appearance index
0.93
Avg. company exit year
10
Avg. multiplicator
3.77
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Imago BioSciences 19 Nov 2020 Biotechnology, Medical, Life Science Late Stage Venture 80M United States, California
TMON 10 Jan 2011 E-Commerce, Information Technology, Mobile Late Stage Venture 8M Gyeonggi-do, South Korea, South Korea

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.